News

Charité and Sanofi broaden alliance
Enlarge image

BusinessGermanyFrance

Charité and Sanofi broaden alliance

28.09.2012 - German university hospital Charité and French pharma company Sanofi have agreed to expand their joint research efforts to the field of diabetes.

The partnership of the Charité and Sanofi had begun in summer 2010, initially with a focus in the field of stroke research. Following a decision on 27 September, scientists and clinicians from both sides will now work together in the field of diabetes research as well. The goal is to better understand the medical needs of patients and to find new targeted approaches to cure or treat the disease.

The partners have already agreed on a first target molecule to investigate further. Researchers from Charité discovered the yet undisclosed molecule, which will now fuel a core project at the newly founded Sanofi-Charité-diabetic laboratory. The target molecule seems to be promising, as results from laboratory tests indicate that it inhibition might protect the body from diet-and age-induced obesity and insulin resistance. “With Charité we have built a highly efficient scientific cooperation over the past two years,” said Jochen Maas, Director of Research and Development of Sanofi-Aventis Deutschland GmbH and head of the German research and development center of Sanofi.

Karl Max Einhäupl, CEO of the Charité, welcomed the enhanced cooperation as well: “Diabetes is a major challenge for our health system. Bringing together the clinical experience and the academic performance of physicians and scientists of the Charité with the development and application expertise of Sanofi, will generate valuable inputs for the development of successful diabetes therapies.”

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2012-03/charite-and-sanofi-broaden-alliance.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • EVOCUTIS (UK)0.18 GBP-10.00%
  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%

TOP

  • KARO BIO (S)38.10 SEK2311.4%
  • TRANSGENE (F)5.08 EUR78.2%
  • BIOTECH PHARMACON (N)12.60 NOK33.1%

FLOP

  • THROMBOGENICS (B)2.90 EUR-43.0%
  • WILEX (D)2.05 EUR-37.5%
  • BIONOR PHARMA (N)1.28 NOK-37.3%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.93 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 28.08.2015